PolyPeptide Group Past Earnings Performance
Past criteria checks 0/6
PolyPeptide Group's earnings have been declining at an average annual rate of -68.6%, while the Life Sciences industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 5.7% per year.
Key information
-68.6%
Earnings growth rate
-87.6%
EPS growth rate
| Life Sciences Industry Growth | 17.6% |
| Revenue growth rate | 5.7% |
| Return on equity | -7.9% |
| Net Margin | -8.8% |
| Next Earnings Update | 11 Mar 2025 |
Recent past performance updates
Recent updates
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price
Nov 11
PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Oct 21Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)
Sep 16Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Jun 19Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
Mar 14PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Mar 13PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 18Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Mar 23Revenue & Expenses Breakdown
How PolyPeptide Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 324 | -29 | 43 | 1 |
| 31 Mar 24 | 322 | -40 | 42 | 1 |
| 31 Dec 23 | 320 | -51 | 42 | 1 |
| 30 Sep 23 | 300 | -44 | 41 | 1 |
| 30 Jun 23 | 279 | -37 | 40 | 1 |
| 31 Mar 23 | 280 | -14 | 40 | 1 |
| 31 Dec 22 | 281 | 8 | 41 | 1 |
| 30 Sep 22 | 281 | 20 | 40 | 1 |
| 30 Jun 22 | 281 | 33 | 40 | 1 |
| 31 Mar 22 | 281 | 40 | 36 | 1 |
| 31 Dec 21 | 282 | 47 | 32 | 1 |
| 30 Sep 21 | 277 | 48 | 31 | 1 |
| 30 Jun 21 | 271 | 48 | 29 | 1 |
| 31 Mar 21 | 248 | 40 | 28 | 1 |
| 31 Dec 20 | 224 | 31 | 28 | 1 |
| 31 Dec 19 | 203 | 26 | 25 | 1 |
| 31 Dec 18 | 181 | 24 | 24 | 12 |
Quality Earnings: PPGN is currently unprofitable.
Growing Profit Margin: PPGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PPGN is unprofitable, and losses have increased over the past 5 years at a rate of 68.6% per year.
Accelerating Growth: Unable to compare PPGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PPGN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (4.3%).
Return on Equity
High ROE: PPGN has a negative Return on Equity (-7.94%), as it is currently unprofitable.